Fibrinolytic response to tumor necrosis factor in healthy subjects

Journal of Experimental Medicine

Volumn 174, Issue 3, 1991, Pages 729-732

  Van Der Poll, Tom ^a   Levi, Marcel ^a   Büller, Harry R ^a   Van Deventer, Sander J H ^a   De Boer, Jan P ^a   Hack, C Erik ^a   Ten Cate, Jan W ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FIBRINOLYSIS; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEPTICEMIA; THROMBOSIS; VASCULAR ENDOTHELIUM;

ADULT; ALPHA-MACROGLOBULINS; ENZYME ACTIVATION; FIBRINOLYSIS; HUMAN; MALE; PLASMIN; PLASMINOGEN; PLASMINOGEN INACTIVATORS; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR;

EID: 0025838097     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.174.3.729     Document Type: Article

References (21)

1. Brandtzaeg, P., G.B. Joo, B. Brusletto, and P. Kierulf. 1990. Plasminogen activator inhibitor 1 and 2, a2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease. Thromh Res. 57:271.
2. Tracey, K.J., H. Vlassara, and A. Cerami. 1989. Cachectin/tumour necrosis factor. Lancet. i:1122.
3. Nawroth, P.P., and D.M. Stern. 1986. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med. 163:740.
4. Schleef, R.R., M.P. Bevilacqua, M. Sawdey, M.A. Gimbrone, Jr., and D.J. Loskutoff. 1988. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type I plasminogen activator inhibitor. J. Biol. Chem. 263:5797.
5. Scarpati, E.M., and J.E. Sadler. 1989. Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor.J. Biol Chem. 264:20705.
6. Van Hinsbergh, V.W.M., T. Kooistra, E.A. van den Berg., H.M.G. Princen, W. Fiers, and J.J. Emeis. 1988. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood. 72:1467.
7. Bauer, K.A., H. ten Cate, S. Barzegar, D.R. Spriggs, M.L. Sherman, and R.D. Rosenberg. 1989. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood. 74:165.
8. Silverman, P., G.H. Goldsmith, Jr., T.R. Spitzer, E.H. Rehmus, and N.A. Berger. 1990. Effect of tumor necrosis factor on the human fibrinolytic system. J. Clin. Oncol. 8:468.
9. Van Hinsbergh, V.W.M., K.A. Bauer, T. Kooistra, C. Kluft, G. Dooijewaard, M.L. Sherman, and W. Nieuwenhuizen. 1990. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin-(ogen) degradation products. Blood. 76:2284.
10. Van der Poll, T., H.R. Büller, H. ten Cate, C.H. Wortel, K.A. Bauer, S.J.H. van Deventer, C.E. Hack, H.P. Sauerwein, R.D. Rosenberg, and J.W. ten Cate. 1990. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N. Engl. J. Med. 322:1622.
11. Verheijen, J.H., E. Mullaart, G.T.G. Chang, C. Kluft, and G. Wijngaards. 1982. A simple sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromh. Haemostas 48:266.
12. Binnema, D.J., J.J.L. van Iersel, and G. Dooijewaard. 1986. Quantitation of urokinase antigen in plasma and culture media by use of an ELISA. Thromh. Res. 43:569.
13. Holvoet, P., H. Cleemput, and D. Collen. 1985. Assay of human tissue-type plasminogen activator with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromh. Haemostas. 54:684.
14. Elms, M.J., I.H. Bruce, P.G. Bundesen, D.B. Rylatt, A.J. Webber, P.P. Masci, and A.N. Whitaker. 1983. Measurement of cross-linked fibrin degradation products. An immunoassay during monoclonal antibodies. Thromh. Haemostas. 50:591.
15. Peters, M., C. Breederveld, L.M. Kahle, and J.W. ten Cate. 1982. Rapid microanalysis of coagulation parameters by automated chromogenic substrate methods-application in neonatal patients. Thromh Res. 28:773.
16. Levi, M., C.E. Hack, J.P. de Boer, D.P.M. Brandjes, H.R. Biiller, and J.W. ten Cate. 1991. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients: further evidence for the role of the contact system in fibrinolysis in vivo. J. Clin. Invest. In press.
17. Van Hinsberg, V.W.M., E.A. van der Berg, W. Fiers, and G. Dooijewaard. 1990. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood. 75:1991.
18. Bevilacqua, M.P., R.R. Schleef, M.A. Gimbrone, Jr., and D.J. Loskutoff. 1986. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. J. Clin. Invest. 78:587.
19. Hanss, M., and D. Collen. 1987. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin and histamine. J. Lah Clin. Med. 109:97.
20. Suffredini, A.F., P.C. Harpel, and J.E. Parrillo. 1989. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N. Engl. J. Med. 320:1165.
21. Van Deventer, S.J.H., H.R. Biiller, J.W. ten Cate, L.A. Aarden, C.E. Hack, and A. Sturk. 1990. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood. 76:2520.